Updates
** Shares of drugmaker Amgen AMGN.O gain 5.54% to $305.04, reversing premarket losses
** Co on Tuesday reported Q4 profit of $5.31 per share, beating estimates of $5.08 - LSEG data
** Said late-stage studies of key obesity drug candidate MariTide will start before mid-year
** However, U.S. FDA has placed clinical hold on early-stage trial of experimental weight-loss drug AMG 513
** AMGN does not believe issue leading to the hold is drug-related
** Obesity will continue to be key theme for Amgen shares as we enter 2025, brokerage BMO Capital Markets says
** Up to last close, stock down ~10% in last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。